Navigation Links
Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer

. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies, Vion is also evaluating VNP40541, a hypoxia-selective compound, and hydrazone compounds. The Company also is seeking development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's Internet web site at www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Annual Report on Form 10-K for the year ended December 31, 2006. In particular, there can be no assurance as to the results of any of the Company's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises un
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:1/15/2014)...  Novation, the leading health care supply chain expertise, analytics ... (VAR) national contracts that expand its portfolio to provide ... costs. These include manufacturer product and service agreements, as ... ongoing IT consulting support. New Novation ...
(Date:1/15/2014)... January 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ...
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... WATERTOWN, Mass., Oct. 17 EnVivo ... developing drugs for,neurodegenerative diseases, today announced ... Alzheimer,s, Schizophrenia and Huntington,s,diseases. EnVivo ... orally,active Alpha 7 Nicotinic Acetylcholine Receptor ...
... VICL ) today announced that an independent data safety ... of the,company,s Phase 2 trial of a DNA vaccine ... safety data after the two-month,follow-up visits for the first ... study. Because most HCT recipients are expected to ...
Cached Medicine Technology:EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimer's, Schizophrenia and Huntington's Diseases 2Interim Safety Data Favorable for Vical's Phase 2 Trial of DNA Vaccine Against CMV 2Interim Safety Data Favorable for Vical's Phase 2 Trial of DNA Vaccine Against CMV 3Interim Safety Data Favorable for Vical's Phase 2 Trial of DNA Vaccine Against CMV 4
(Date:4/17/2014)... genetic variant specifically associated with the risk of ... per cent of all breast cancer cases. , ... sub-type, called invasive lobular carcinoma, gives researchers important ... kind of breast cancer, which can be missed ... in the journal PloS Genetics , was ...
(Date:4/17/2014)... Biology and Medicine a multidisciplinary research team ... in the Institute of Genomic Biology (IGB) on ... describe their recent work on subcellular redox homeostasis. ... functions including energy metabolism, signaling, and transcriptional processes. ... cellular behavior, redox status has been recognized as ...
(Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
(Date:4/17/2014)... many as 10 million older Americans suffer from depression, ... , However, new research a project that followed ... six years found that Internet use among the ... than 30 percent. , "That,s a very strong effect," ... telecommunication, information studies and media who led the project. ...
(Date:4/17/2014)... School of Medicine (BUSM) have discovered that the ... experimental model. The findings, reported in the ... may lead to more effective treatments for alcoholism. ... the leading causes of illness and death in ... by limiting the productivity of workers and necessitating ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... (Nasdaq: HRLY ) announced today that its ... $1 million from a major,U.S. defense contractor for ... U.S. Air Force jet fighters., Myron Levy, ... hardware to support U. S. Air Force military ...
... SAN DIEGO, April 22 Cardium Therapeutics,(Amex: ... announced today that,InnerCool,s endovascular Celsius Control System will ... Works" series. The segment (episode 5) will,feature InnerCool,s ... scheduled to air on Friday, April 25, 2008 ...
... about the size of a pencil eraser are more likely to ... according to a new study led by NYU Langone Medical Center ... published in the April issue of Archives of Dermatology, the NYU ... that are larger than 6 millimeters, the size of a pencil ...
... /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, Inc. (OTC Bulletin Board: CHBT) ("China-Biotics," ... manufacture,research, development, marketing and distribution of probiotics products,today ... in the,first quarter of 2008. Currently, the Company ... major cities in China., "We are very ...
... Healthcare Due to 77 Percent Revenue Growth, ... Expansion, Key Hires -, ... has been named Healthcare Agency of the Year by The,Holmes Report. In ... #16 overall and #4 in healthcare and was the,fastest-growing agency in the ...
... YORK, April 22 WallSt.net,s 3-Minute,Press Show is ... Tracee,Tolentino., Shows air Monday through Friday ... features in-depth interviews with,public company executives on their ... designed to provide viewers with insight into a ...
Cached Medicine News:Health News:Herley Awarded $1 Million in Awards for Integrated Microwave Assemblies for U.S. Military Aircraft 2Health News:Cardium Announces InnerCool's Endovascular Cooling to be Featured on Science Channel's Series 'Cool Stuff: How It Works' 2Health News:Cardium Announces InnerCool's Endovascular Cooling to be Featured on Science Channel's Series 'Cool Stuff: How It Works' 3Health News:Cardium Announces InnerCool's Endovascular Cooling to be Featured on Science Channel's Series 'Cool Stuff: How It Works' 4Health News:Melanoma lurks in larger skin lesions, NYU researchers find 2Health News:China-Biotics, Inc. Expands Retail Network to 60 Shining Retail Centers 2Health News:China-Biotics, Inc. Expands Retail Network to 60 Shining Retail Centers 3Health News:WeissComm Partners Named Healthcare Agency of the Year 2Health News:Featured Stocks on Today's Edition of WallSt.net's 3-Minute Press Show: CYRX, RHWI 2
Reagent Basin, 60mL, 5/Box...
Reservoir, 8 Well, 10/Box...
... manually adjustable dispensing head, and disposable, pre-sterilized ... cost-efficiency to microplate fluid dispensing. It is ... offer fast dispensing of fluids in a ... It also offers the added benefit of ...
The WellPro 384 is designed for use with 384 well microplates. It utilizes a 24 channel liquid head and can perform serial dilutions in a 16 or 24 across format, and plate to plate transfers and plat...
Medicine Products: